Baidu
map

Nature Medicine:激活小肠FXR,向肥胖说不!

2015-02-09 佚名 生物谷

近日,著名国际期刊Nature Medicine发表了美国科学家的一项最新研究成果,他们发现特异性激活肠道FXR会促进肠道FGF15表达改变胆汁酸组成成分,同时能够通过增加产热以及白色脂肪棕色化,改善肥胖小鼠的体重及代谢恶化表型。   研究人员指出,目前利用胆汁酸感应因子FXR的全身性表达靶向胆固醇代谢,甘油三酯合成,肝脏脂肪变性和胆汁淤积治疗相关疾病正成为新兴疗法。相比于全身性治疗

近日,著名国际期刊Nature Medicine发表了美国科学家的一项最新研究成果,他们发现特异性激活肠道FXR会促进肠道FGF15表达改变胆汁酸组成成分,同时能够通过增加产热以及白色脂肪棕色化,改善肥胖小鼠的体重及代谢恶化表型。
 
研究人员指出,目前利用胆汁酸感应因子FXR的全身性表达靶向胆固醇代谢,甘油三酯合成,肝脏脂肪变性和胆汁淤积治疗相关疾病正成为新兴疗法。相比于全身性治疗方法,在进食情况下选择性释放胆汁酸能够激活肠道FXR。通过模拟这种组织特异性效应,利用特异性FXR激动剂fexaramine能够诱导肠道FGF15表达,从而导致BA成分变化,但是不会激活肝脏中FXR目标基因的表达。但是与全身性表达不同,研究人员发现Fex能够降低饮食诱导的体重增加,改善全身性炎症和肝脏葡萄糖产生,同时伴有产热增加以及白色脂肪棕色化的现象。
 
综上所述,该文章发现肠道特异性激活FXR能够改善小鼠肥胖及代谢恶化表型,促进机体产热以及白色脂肪棕色化,这些代谢改善表明组织特异性抑制FXR激活可作为治疗肥胖和代谢综合征的新疗法。

原始出处

Fang S1, Suh JM1, Reilly SM2, Yu E1, Osborn O3, Lackey D3, Yoshihara E1, Perino A4, Jacinto S1, Lukasheva Y1, Atkins AR1, Khvat A5, Schnabl B3, Yu RT1, Brenner DA3, Coulter S6, Liddle C6, Schoonjans K4, Olefsky JM3, Saltiel AR2, Downes M1, Evans RM7.Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance.Nat Med. 2015 Feb

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1773478, encodeId=0b501e73478e9, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu May 28 12:05:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880496, encodeId=0414188049661, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Sep 02 15:05:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858601, encodeId=72a01858601c0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Apr 30 04:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16693, encodeId=84f0166939a, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:20:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16255, encodeId=95211625543, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:03:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15854, encodeId=b5b3158540e, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:23:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577419, encodeId=08b615e74190e, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606401, encodeId=5ab2160640128, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622046, encodeId=fd89162204616, content=<a href='/topic/show?id=b506e7489b' target=_blank style='color:#2F92EE;'>#FXR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7748, encryptionId=b506e7489b, topicName=FXR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
    2015-05-28 kalseyzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1773478, encodeId=0b501e73478e9, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu May 28 12:05:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880496, encodeId=0414188049661, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Sep 02 15:05:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858601, encodeId=72a01858601c0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Apr 30 04:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16693, encodeId=84f0166939a, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:20:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16255, encodeId=95211625543, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:03:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15854, encodeId=b5b3158540e, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:23:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577419, encodeId=08b615e74190e, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606401, encodeId=5ab2160640128, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622046, encodeId=fd89162204616, content=<a href='/topic/show?id=b506e7489b' target=_blank style='color:#2F92EE;'>#FXR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7748, encryptionId=b506e7489b, topicName=FXR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
    2015-09-02 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1773478, encodeId=0b501e73478e9, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu May 28 12:05:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880496, encodeId=0414188049661, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Sep 02 15:05:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858601, encodeId=72a01858601c0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Apr 30 04:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16693, encodeId=84f0166939a, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:20:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16255, encodeId=95211625543, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:03:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15854, encodeId=b5b3158540e, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:23:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577419, encodeId=08b615e74190e, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606401, encodeId=5ab2160640128, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622046, encodeId=fd89162204616, content=<a href='/topic/show?id=b506e7489b' target=_blank style='color:#2F92EE;'>#FXR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7748, encryptionId=b506e7489b, topicName=FXR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
    2015-04-30 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1773478, encodeId=0b501e73478e9, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu May 28 12:05:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880496, encodeId=0414188049661, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Sep 02 15:05:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858601, encodeId=72a01858601c0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Apr 30 04:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16693, encodeId=84f0166939a, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:20:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16255, encodeId=95211625543, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:03:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15854, encodeId=b5b3158540e, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:23:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577419, encodeId=08b615e74190e, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606401, encodeId=5ab2160640128, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622046, encodeId=fd89162204616, content=<a href='/topic/show?id=b506e7489b' target=_blank style='color:#2F92EE;'>#FXR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7748, encryptionId=b506e7489b, topicName=FXR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
    2015-02-22 orthoW

    不错的文章,学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1773478, encodeId=0b501e73478e9, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu May 28 12:05:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880496, encodeId=0414188049661, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Sep 02 15:05:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858601, encodeId=72a01858601c0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Apr 30 04:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16693, encodeId=84f0166939a, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:20:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16255, encodeId=95211625543, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:03:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15854, encodeId=b5b3158540e, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:23:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577419, encodeId=08b615e74190e, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606401, encodeId=5ab2160640128, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622046, encodeId=fd89162204616, content=<a href='/topic/show?id=b506e7489b' target=_blank style='color:#2F92EE;'>#FXR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7748, encryptionId=b506e7489b, topicName=FXR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
    2015-02-17 chinayinhan

    已阅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1773478, encodeId=0b501e73478e9, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu May 28 12:05:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880496, encodeId=0414188049661, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Sep 02 15:05:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858601, encodeId=72a01858601c0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Apr 30 04:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16693, encodeId=84f0166939a, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:20:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16255, encodeId=95211625543, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:03:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15854, encodeId=b5b3158540e, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:23:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577419, encodeId=08b615e74190e, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606401, encodeId=5ab2160640128, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622046, encodeId=fd89162204616, content=<a href='/topic/show?id=b506e7489b' target=_blank style='color:#2F92EE;'>#FXR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7748, encryptionId=b506e7489b, topicName=FXR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
    2015-02-16 windmilL1989

    已阅

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1773478, encodeId=0b501e73478e9, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu May 28 12:05:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880496, encodeId=0414188049661, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Sep 02 15:05:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858601, encodeId=72a01858601c0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Apr 30 04:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16693, encodeId=84f0166939a, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:20:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16255, encodeId=95211625543, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:03:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15854, encodeId=b5b3158540e, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:23:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577419, encodeId=08b615e74190e, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606401, encodeId=5ab2160640128, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622046, encodeId=fd89162204616, content=<a href='/topic/show?id=b506e7489b' target=_blank style='color:#2F92EE;'>#FXR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7748, encryptionId=b506e7489b, topicName=FXR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1773478, encodeId=0b501e73478e9, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu May 28 12:05:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880496, encodeId=0414188049661, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Sep 02 15:05:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858601, encodeId=72a01858601c0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Apr 30 04:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16693, encodeId=84f0166939a, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:20:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16255, encodeId=95211625543, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:03:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15854, encodeId=b5b3158540e, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:23:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577419, encodeId=08b615e74190e, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606401, encodeId=5ab2160640128, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622046, encodeId=fd89162204616, content=<a href='/topic/show?id=b506e7489b' target=_blank style='color:#2F92EE;'>#FXR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7748, encryptionId=b506e7489b, topicName=FXR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1773478, encodeId=0b501e73478e9, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu May 28 12:05:00 CST 2015, time=2015-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880496, encodeId=0414188049661, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Sep 02 15:05:00 CST 2015, time=2015-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858601, encodeId=72a01858601c0, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Apr 30 04:05:00 CST 2015, time=2015-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16693, encodeId=84f0166939a, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sun Feb 22 09:20:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16255, encodeId=95211625543, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 01:03:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15854, encodeId=b5b3158540e, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:23:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577419, encodeId=08b615e74190e, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606401, encodeId=5ab2160640128, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622046, encodeId=fd89162204616, content=<a href='/topic/show?id=b506e7489b' target=_blank style='color:#2F92EE;'>#FXR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7748, encryptionId=b506e7489b, topicName=FXR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Feb 11 00:05:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
    2015-02-11 爆笑小医

相关资讯

Nature:2型先天淋巴样细胞可促进脂肪米色化遏制肥胖

随着人类生活方式的西化,世界人口的肥胖率越来越高,而这一疾病通常由遗传因素和环境因素共同影响。最新研究表明包括单核细胞、粒细胞和淋巴细胞在内的免疫细胞参与了机体的稳态代谢平衡调控,但是在肥胖的个体中研究者们发现这些免疫细胞的功能出现了异常。 2型先天淋巴样细胞(ILC2s)能够调控获得性免疫反应以及嗜酸性粒细胞和可变激活巨噬细胞产生的免疫反应。近年来研究者们从小鼠的白色脂肪组织(WAT)中分离到

AJCN:孕前改善机体健康或可有效抑制后代肥胖

近日,一项刊登在国际杂志The American Journal of Clinical Nutrition上的研究论文中,来自南安普顿大学的研究人员通过研究发现,女性孕前改善机体健康或者可以帮助有效预防个体后代肥胖;文章中研究者为揭示儿童早期生长环境和后期患肥胖间的关系又提供了新的研究证据,此前研究者鉴别出了一系列风险因子,但却很少评估其对肥胖的联合效应。 这项研究中研究者发现了许多可以预

Cell Metab:限时饮食可以预防甚至逆转肥胖

长期以来,母亲们都认为不宜在半夜吃零食,科学家们对此也持有相同的看法。但直到几年前,人们也只是有此怀疑,却没有多少科学证据可以支持它。现在,一项在小鼠中进行的新研究显示,即使有时候它们的饮食不够健康,但只要不是一天到晚吃个不停,就可避免肥胖和代谢问题。 在此前的一项研究中,美国圣地亚哥索尔克生物研究所(Salk Institute for Biological Studies)和其他机构的研究

Lancet Oncol:肥胖增加癌症发生风险

背景:高体质指数(即高BMI,定义为大于等于25kg/m2)是多种慢性疾病和死亡的危险因素。全世界的超重和肥胖问题不断加重,由此对健康造成的危害引起了人们的关注。多项研究显示,高BMI与癌症发生风险增高有关,包括食管腺癌、结肠癌、直肠癌、肾癌、胰腺癌、女性胆囊癌、绝经后乳腺癌、卵巢癌及子宫内膜癌。但已有研究未考虑高BMI导致新发癌症的时滞(lag time,即高BMI导致癌症的发生需要一定的时间)

Diabetes:脂联素抗炎记——肥胖群体中也有“好”胖子?

近日,国际糖尿病学杂志Diabetes 刊登了来自曼彻斯特大学David W. Ray研究小组的一项最新研究成果,他们发现在肥胖人群中,一种TLR信号负调控因子A20的表达与胰岛素敏感性呈明显相关性,并且在经过肥胖症治疗手术之后的个体中,A20的表达与血清中脂联素呈现明显的正相关性并伴随代谢和炎症的改善,该小组通过小鼠模型证明了A20对于脂联素发挥抗炎效应具有调控作用。 研究人员指出,脂联素是白

点评:继续寻找2型糖尿病的基因是否有价值?

2型糖尿病是一种高度异质性的疾病,在复杂的基因背景下,营养物质过多摄入导致体内糖脂代谢异常,引起疾病发生。因此,遗传和环境是2型糖尿病发生的两大重要方面。正方Mark McCarthy和反方Mike Lean正是从这两个方面来看待目前关于2型糖尿病的研究。在遗传学方面,正如Mark McCarthy所说,通过GWAS研究和一些表观遗传学的研究从基础研究的角度在一定程度上揭示了基因在2型糖尿病发生中

Baidu
map
Baidu
map
Baidu
map